CSPG4 and melanoma: Using commercially available and our own engineered CSPG4-specific antibodies, we demonstrated CSPG4 expression in malignant melanoma, including in lymph and distant metastases, and absent/low expression in normal tissues (Figs. 1, 2)1,42,44,45, together supporting the potential of CSPG4 as a specific tumor-associated therapeutic target.